Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Prostate Cancer, Castration Resistant”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07310355
What this trial is testing

68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Chengdu StarRay Therapeutics Co., Ltd 49
Testing effectiveness (Phase 2)UnknownNCT02254785
What this trial is testing

Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostatic Cancer
British Columbia Cancer Agency 120
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06836726
What this trial is testing

Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer

Who this might be right for
Castration Resistant Prostate Cancer
University Health Network, Toronto 35
Post-approval studies (Phase 4)Study completedNCT02485691
What this trial is testing

Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent

Who this might be right for
Prostate Cancer Metastatic
Sanofi 255
Early research (Phase 1)Ended earlyNCT03861403
What this trial is testing

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced Triple Negative Breast CancerAdvanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer+2 more
Leap Therapeutics, Inc. 10
Testing effectiveness (Phase 2)WithdrawnNCT06329830
What this trial is testing

177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer

Who this might be right for
Metastatic Prostate CancerCastration-resistant Prostate CancerMetastatic Castration-resistant Prostate Cancer
Baptist Health South Florida
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07164794
What this trial is testing

Memantine Hydrochloride in Prostate Cancer Patients

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostate CancerNeuroendocrine Prostate Cancer (NEPC)
Bin Xu 15
Early research (Phase 1)Ended earlyNCT05124795
What this trial is testing

IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Immunic AG 18
Early research (Phase 1)Ended earlyNCT04629781
What this trial is testing

Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Swiss Cancer Institute 11
Large-scale testing (Phase 3)Active Not RecruitingNCT03395197
What this trial is testing

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

Who this might be right for
mCRPC
Pfizer 1,054
Large-scale testing (Phase 3)Study completedNCT04100018
What this trial is testing

Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Bristol-Myers Squibb 1,030
Testing effectiveness (Phase 2)Looking for participantsNCT06990880
What this trial is testing

GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

Who this might be right for
Neoplasms, Prostate
GlaxoSmithKline 85
Early research (Phase 1)Study completedNCT01228760
What this trial is testing

Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Neoplasms
Astellas Pharma Inc 46
Testing effectiveness (Phase 2)Looking for participantsNCT06401980
What this trial is testing

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Swiss Cancer Institute 162
Early research (Phase 1)Not Yet RecruitingNCT07090369
What this trial is testing

Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Peter MacCallum Cancer Centre, Australia 20
Testing effectiveness (Phase 2)Study completedNCT02692976
What this trial is testing

Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients

Who this might be right for
Prostatic NeoplasmsImmunotherapyDendritic Cells+1 more
Radboud University Medical Center 21
Early research (Phase 1)Looking for participantsNCT06826768
What this trial is testing

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

Who this might be right for
Prostate Cancer
M.D. Anderson Cancer Center 60
Testing effectiveness (Phase 2)Ended earlyNCT02555189
What this trial is testing

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaProstate Carcinoma Metastatic in the Bone+1 more
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 52
Early research (Phase 1)Ended earlyNCT05252390
What this trial is testing

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorOvarian CancerOvary Cancer+24 more
Nuvation Bio Inc. 82
Testing effectiveness (Phase 2)Study completedNCT00853697
What this trial is testing

Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer

Who this might be right for
Prostate CancerCastration-resistant, Metastatic
Memorial Sloan Kettering Cancer Center 6
Next Page